The New England journal of medicine, 2017-10, Vol.377 (14), p.1345-1356
- Wolchok, Jedd D
- Chiarion-Sileni, Vanna
- Gonzalez, Rene
- Rutkowski, Piotr
- Grob, Jean-Jacques
- Cowey, C. Lance
- Lao, Christopher D
- Wagstaff, John
- Schadendorf, Dirk
- Ferrucci, Pier F
- Smylie, Michael
- Dummer, Reinhard
- Hill, Andrew
- Hogg, David
- Haanen, John
- Carlino, Matteo S
- Bechter, Oliver
- Maio, Michele
- Marquez-Rodas, Ivan
- Guidoboni, Massimo
- McArthur, Grant
- Lebbé, Celeste
- Ascierto, Paolo A
- Long, Georgina V
- Cebon, Jonathan
- Sosman, Jeffrey
- Postow, Michael A
- Callahan, Margaret K
- Walker, Dana
- Rollin, Linda
- Bhore, Rafia
- Hodi, F. Stephen
- Larkin, James
2017
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Wolchok, Jedd D
- Chiarion-Sileni, Vanna
- Gonzalez, Rene
- Rutkowski, Piotr
- Grob, Jean-Jacques
- Cowey, C. Lance
- Lao, Christopher D
- Wagstaff, John
- Schadendorf, Dirk
- Ferrucci, Pier F
- Smylie, Michael
- Dummer, Reinhard
- Hill, Andrew
- Hogg, David
- Haanen, John
- Carlino, Matteo S
- Bechter, Oliver
- Maio, Michele
- Marquez-Rodas, Ivan
- Guidoboni, Massimo
- McArthur, Grant
- Lebbé, Celeste
- Ascierto, Paolo A
- Long, Georgina V
- Cebon, Jonathan
- Sosman, Jeffrey
- Postow, Michael A
- Callahan, Margaret K
- Walker, Dana
- Rollin, Linda
- Bhore, Rafia
- Hodi, F. Stephen
- Larkin, James
- Titel
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Ist Teil von
- The New England journal of medicine, 2017-10, Vol.377 (14), p.1345-1356
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2017
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Both nivolumab alone and nivolumab plus ipilimumab resulted in longer overall survival among patients with previously untreated advanced melanoma than ipilimumab alone. The combination was associated with a higher rate of toxic effects.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1709684Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5706778
- Format
- –
- Schlagworte
- Adult, Aged, Antibodies, Monoclonal - administration & dosage, Antibodies, Monoclonal - adverse effects, Antineoplastic Combined Chemotherapy Protocols - adverse effects, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Body weight, Cancer therapies, Clinical trials, Death, Disease-Free Survival, Double-Blind Method, Drug dosages, Humans, Immunotherapy, Ipilimumab, Kaplan-Meier Estimate, Ligands, Medical research, Melanoma, Melanoma - drug therapy, Melanoma - mortality, Metastases, Middle Aged, Monoclonal antibodies, Mutation, Neoplasm Staging, Nivolumab, Oncology, PD-L1 protein, Skin Neoplasms - drug therapy, Skin Neoplasms - mortality, Survival, Survival Rate, Targeted cancer therapy